xport in crescita nel Pesarese: +6,4% nel primo semestre, raggiunti 1,78 miliardi di euro

A simple scaling law brings order to the chaos of flowing water, rock, and sediment. New findings have extended the law even further.

The phase III XPORT-EC-042 trial, evaluating selinexor as a maintenance-only therapy compared to placebo in adult patien

Reported Thursday, Jul 30 - 6:19pm EDT (TheFly subscription required to read more.)

Karyopharm Therapeutics (Nasdaq: KPTI) reported topline Phase 3 results from the global XPORT-EC-042 trial evaluating once-weekly oral selinexor as maintenance monotherapy versus placebo in 257 adults with TP53 wild-type advanced or recurrent endometrial cancer.The trial did not meet its primary endpoint of progression-free survival (PFS). In the modified intent-to-treat (mITT) population (n=236), median PFS was 12.75 months with selinexor versus 7.43 months with placebo (hazard ratio 0.76; 95% CI: 0.51–1.12; one-sided p=0.0791), corresponding to a 5.3‑month difference favoring selinexor. As of data cut-off, 106 PFS events had occurred in the mITT group.The safety and tolerability of selinexor were consistent with its established profile, and no new safety signals were observed. Karyopharm will fully analyze the dataset, continue to follow patients for longer-term outcomes, and plans to present detailed results at a future medical meeting. The company said these findings do not affect ongoing selinexor trials in other indications and that it will reduce planned investment in endometrial cancer while prioritizing its myelofibrosis and multiple myeloma programs, with several myelofibrosis milestones expected in the second half of 2026.

Sokoban on a leash

Lantronix XPort device is affected by a critical vulnerability that can be used for takeover and disruption, including in the energy sector.

Lantronix XPort device is affected by a critical vulnerability that can be used for takeover and disruption, including in the energy sector.

Copy Slack search results as Markdown-formatted YAML, ready to paste into LLM prompts.

Etihad Credit Insurance (ECI), the UAE’s federal export credit company, announced the impact of its ‘Xport Xponential’ programme, which has helped raise AED 174 million in funding to support the growth of SMEs, during the closing ceremony of the programme. The working capital was raised with the support of four of ECI’s banking partners: First Abu Dhabi Bank, Commercial Bank of Dubai, Ajman Bank, and Al Maryah Community Bank.

10 track album